Ethyl iodide (0.61 ml) was then added to the mixture 0 °C, and the resulting mixture was stirred at room temperature for 3 h. Water was added to the mixture, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to give a crude product (0.98 g).
A 4.0 M sodium hydroxide aqueous solution (3.0 ml) was added too a solution of the obtained compound (0.90 g) in methanol (30 ml), and the mixture was stirred at reflux for 3 h. The mixture was concentrated, and water and ethyl acetate were added to the residue, and the resulting biphasic solution was then separated. The organic layer was washed with 1.0 M hydrochloric acid and brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified on silica gel column chromatography employing a gradient of 99:1 to 90:10 with chloroform/methanol to give compound 6 (0.33 g, 36% 
3-{[2-Ethoxy-5-(trifluoromethyl)benzyl]thio}-N-(phenylsulfonyl)thiophene-2-carboxamide
(NAZ2329): A 60% dispersion of sodium hydride in mineral oil (40 mg) was added to a solution of benzenesulfonamide (0.16 g) in N,N-dimethylformamide (10 ml) at 0 °C, and the mixture was stirred at room temperature for 15 min. The mixture was added to a solution, which was prepared by stirring compound 6 (0.30 g) and 1,1'-carbonyldiimidazole (0.16 g) in N,N-dimethylformamide (10 ml) at room temperature, at 0 °C. The resulting mixture was stirred at room temperature for 2 days and at 50 °C for 5 h. Then, 1.0 M hydrochloric acid was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified on silica gel column chromatography employing a gradient of 99:1 to 90:10 with chloroform/methanol to give NAZ2329 (0.28 g, 67% 
Legends to Supplementary Figures
Supplementary Figure S1 . 
-test).
The Val to Phe mutation of PTPRZ1 and PTPRG hardly affected their sensitivity to SCB4380 or vanadate.
5
The Phe to Val mutation of PTPN1 decreased its vanadate sensitivity, which was inverse to that for NAZ2329.
Supplementary Figure S4 . Effects of the NAZ2329 treatment on human U251 glioblastoma cells.
Effects of NAZ2329 on the proliferation (A), migration (B), and SOX2 expression (C) of human U251
cells. Experiments were performed as in Figure 3 . Images are representative of five independent culture conditions. Scale bars, 100 µm. *, P < 0.05; **, P < 0.01, significantly different from the vehicle (oneway ANOVA with Bonferroni post hoc tests). 
Supplementary
hPTPRG F191V hPTPN1 RZ1 S L P V L T F V R K A A Y RG A L P V L T F V R R S S A R1/R6 RC P H L L L K L R R R V N A RM A T G L L G F V R Q V K S RK A T G L L S F I R R V K L RT A T G L L G F V R Q V K F RU A T G L L A F I R R V K A RD P T P F L A F L R R V K T RF P T P I L A F L R R V K A RS P T P F L A F L R R V K T RB T Q S L I Q F V R T V R D RH T L L A F W R M L R Q W L RJ L L I N F R Y L V R D Y M RO RQ A E S I L Q F V H M V R Q S A P L I H F V K L V R A RA P I G M L K F L K K V K A RE P I G M L K F L K K V K T RR A Q P L L Q L M L D V E E N5 A P P L L H L V R E V E E N7 A G P L L R L V A E V E E RN T R P L L D F R R K V N K RN2 S R S L L D F R R K V N K N1 P A S F L N F L F K V R E N2 P A S F L N F L F K V R E N6 P G G V L S F L D Q I N Q N11 P G G V L D F L E E V H H NT3 N9 A A S L I D F L R V V R N N12 F D S I L D M I S L M R K N18 P D H M L A M V E E A R R N22 I D P I L E L I W D V R C N3 S S D F L E F V N Y V R S N4 S S D F L D F V C H V R N N14 V Q G F L S Y L E E I Q S N21 L K G F L S Y L E E I Q S NT7 N13 P D D L L T F I S Y M R H NT8 N20 A D S F I K Y I R Y A R K NT9 N23 P S N L L R F I Q E V H A --K T F E L I S V I K E --S T F E L I N V I K E P K E L I S M I Q V V K Q K R S F L K L I R Q V D K K R S F L K L I L Q V E K K R S L L K V V R R L E K K K A F L H L L A E V D K G K G M I S I I A A V Q K G K G M I D L I A A V Q K G E G F I D F I G Q V H K G E G F I D F I G Q V H K G E G F I D F I G Q V H K NT6 R5 α3-helix (PTP-D1) α3-
